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Short summary (30 words) 
 
An evaluation of two commercial HSV-2 ELISAs (HerpeSelect® and KalonTM), compared 
to HSV-2 Western Blot, found that co-infection with HIV-1 markedly reduced the 
specificity of the commercial assays. 
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Abstract (245 words) 
 
Introduction: Sero-epidemiological studies of herpes simplex virus type-2 (HSV-2) 
infection in Africa remain difficult to interpret owing to the high rate of false-positive 
results observed when using the new recombinant gG2 HSV-2 ELISA tests. We 
compared the performance of two widely used gG2 ELISAs to derive an appropriate 
testing algorithm for use in South Africa. 
 
Methods:  Sera from 210 women attending family planning clinics in Johannesburg were 
tested using HerpeSelect® and KalonTM HSV-2 gG2 assays. Sera from 20 discordant 
pairs, 44 concordant positive and 33 concordant negative samples were further tested 
by HSV Western Blot (WB). Sensitivity and specificity of each test and of combination 
algorithms compared to WB were calculated. 
 
Results:  HerpeSelect® had a sensitivity of 98% (95% confidence interval [CI]: 95-100) 
and specificity of 61% (95%CI: 48-74). KalonTM was less sensitive (89%, 95%CI: 83-94) 
but more specific (85%, 95%CI: 61-100). Seroprevalence may have been overestimated 
by as much as 14% by HerpeSelect®.  Specificity was improved by raising the cut-off 
index for determination of a positive result for HerpeSelect® (to ≥3.5), but not for 
KalonTM.  HIV-1 infection reduced the specificity of HerpeSelect® to 30%. Improved 
sensitivity and specificity were obtained by a two-test algorithm using HerpeSelect® 
(≥3.5) as the first test and Kalon™ to resolve equivocal results (sensitivity 92%, 95%CI: 
82-98; specificity 91%, 95%CI: 79-98). 
 
Conclusion: Newer HSV-2 serological tests have low specificity in this South African 
population with high HIV-1 prevalence. Two-step testing strategies could provide rational 
testing alternatives to WB.  
 
Key-words: herpes simplex virus type-2 (HSV-2); HSV serology; HerpeSelect®; 
KalonTM; HIV-1; South Africa 
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INTRODUCTION 
 
Herpes simplex virus type 2 (HSV-2) is a primary cause of genital ulcers and is one of 
the most prevalent sexually transmitted infections worldwide1. Recent serological studies 
conducted among populations with no specific high-risk sexual behaviour characteristics 
in sub-Saharan Africa have shown prevalence rates that exceed those of similar 
populations in the USA and Europe2.  Up to 70% of high-risk HIV-1 seronegative and up 
to 85% of HIV-1 seropositive persons are seropositive for HSV-2 in sub-Saharan Africa2, 
3. However, sero-epidemiological studies of HSV-2 in Africa have been hampered by 
concerns that some of the newer HSV-2 ELISAs are associated with high rates of false-
positive reactions in African sera.  In an evaluation study of thirteen HSV-2 type-specific 
assays, the specificity ranged from 47 to 99%4.  In this evaluation, the HerpeSelect® 
(Focus Technologies) was shown to have a high sensitivity (100%) but a low specificity 
(71%), while the Kalon™ HSV-2 gG2 ELISA was one of the best performing tests 
(sensitivity 93% specificity 98%).  Specificity was shown to be lower in HIV-1 
seropositive individuals. In another study of sera from populations in South Africa, 
Zimbabwe, Kenya and Uganda using the HerpeSelect®5, 100% concordance with 
Western blot (WB) was observed in sera from Zimbabwe and South Africa, but was 
lower for samples from Kenya (96%) and Uganda (88%). More recently, a study 
comparing HerpeSelect® and KalonTM with WB in 120 HIV-1 seronegative men aged 18-
24 years in Kenya showed a lower specificity for HerpeSelect® (40%) compared to 
KalonTM (79%)6. Another more recent study using 538 Ugandan samples tested with WB, 
two ELISA assays and a rapid test (BiokitTM) confirmed the lower specificity of 
HerpeSelect® (51%) which was improved by raising the cut-off value for positive results 
to 3.2. In the same study, the specificity of the KalonTM assay was found to be superior to 
HerpeSelect®; this was enhanced further by raising the cut-off for positive results to 1.5 
which increased specificity from 88% to 92%7. This study did not find any significant 
difference in assay performance by HIV-1 serostatus. 
 
While sensitive tests are more useful for diagnosis, higher levels of specificity are 
required in epidemiological studies where associations with other infections like HIV-1 
are explored. Highly specific testing strategies are required to identify individuals who 
might benefit from HSV treatment interventions currently being evaluated in trials. Large-
scale WB testing is costly, and not feasible in many settings in Africa. For these reasons, 
Page 5 of 17 
a comparative evaluation of the sensitivity and specificity of two HSV-2 specific ELISA-
based serological assays was undertaken in a South African population where HIV-1 
and HSV-2 prevalence are both high8.9, 10 
 
MATERIALS AND METHODS 
 
A total of 210 women aged 18-46 years were recruited from a family planning clinic in 
Johannesburg, South Africa, during the period from August to November 2003. Serum 
samples collected from consenting women of unknown HSV-2 serostatus were tested for 
HSV-2 using the HerpeSelect® ELISA (Focus Technologies Inc., Cypress Hill, Ca) and 
the KalonTM HSV-2 gG2 ELISA (Kalon Biologicals Ltd, Aldershot, UK).  Optical density 
(OD) readings for KalonTM and the normalized OD readings for HerpeSelect® were 
recorded. Samples with normalised OD readings <0.9 were recorded as negative, those 
with values >1.1 were recorded as positive, and those with intermediate values (0.9-1.1) 
were recorded as equivocal as per manufacturer’s instructions.  
 
Using a pre-determined sampling strategy, a random selection of specimens with 
concordant results and all discordant results (with serum remaining) were shipped to the 
University of Washington, Seattle, USA, for evaluation using a gold standard WB assay 
which has been previously described11.  Samples with remaining serum were tested for 
HIV-1 using Abbott AxSYM HIV 1/2 gO (Abbott Diagnostics, Wiesbaden-Delkenheim, 
Germany) in South Africa only when it became apparent that HIV-1 serostatus might 
influence HSV-2 ELISA results4. Indeterminate results were resolved using BioRad 
Genetic Systems rLAV HIV-1 ELISA (BioRad Laboratories, Redmond, USA).  
 
The sensitivity and specificity of the different tests were calculated, taking into account 
the sampling strategy, according to methods described by Hawkins et al12.  Only 
samples with (normalised) OD readings >1.1 were considered positive. Additional 
analyses were performed to investigate whether sensitivity and/or specificity of the tests 
could be improved by changing the cut-off values for positive specimens using receiver 
operator characteristic (ROC) curves and likelihood ratios. We specifically investigated 
the sensitivity and specificity of a higher cut-off value for HerpeSelect® of ≥3.5 as has 
been suggested by other authors5, 13. The effect of age and HIV-1 serostatus on 
sensitivity and specificity were also explored.  
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All participants were volunteers who gave written informed consent to participate prior to 
any study-related procedures.  This study was approved by the Human Research Ethics 
Committee of the University of the Witwatersrand and the research ethics committee of 
the London School of Hygiene & Tropical Medicine, and was conducted in accordance 
with good clinical and laboratory practice guidelines. 
 
RESULTS 
 
Population characteristics 
Participants had a mean age of 25.6 years (range 18-46). The overall HSV-2 
seroprevalence for this population varied by as much as 14%, depending on the test 
used.  Of the 210 specimens tested, 168 (80%) of women were HSV-2 seropositive, 40 
(19%) were negative, and 2 results (1%) were equivocal using HerpeSelect®. With the 
Kalon™ assay, 138 (66%) of the samples were HSV-2 seropositive, 58 (28%) were 
seronegative, and 14 (7%) results were equivocal. HIV-1 results were available for 145 
(69%) participants.  The overall HIV-1 prevalence was 52%. 
 
The results of testing using HerpeSelect® and Kalon™ were compared. Of the 210 
samples tested, 178 (85%) had concordant results for both tests: 138 (66%) were 
concordant positive, 42 (20%) were concordant negative and none were equivocal on 
both tests.  Thirty-two specimens (15%) specimens had discordant results. In the 
samples with discordant results, the majority (n=30) were positive on HerpeSelect® but 
either negative (n=16) or equivocal (n=14) on Kalon™. In two cases, samples were 
equivocal on HerpeSelect® and negative with Kalon™.  Overall, HerpeSelect® 
appeared to detect positive specimens more frequently than Kalon™ (see table 1).  
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Table 1.  Comparison of HerpeSelectTM and KalonTM test results with resolver 
Western Blot test for HSV-2 (WB) among 210 South African sera. 
HerpeSelect 
test result 
Kalon 
test 
result 
Number and % 
of samples 
  
Number 
tested with 
resolver test 
(WB) 
Number and % 
positive with 
resolver test (WB) 
Positive Positive 138 66% 44 41 93% 
Positive Negative 301 14% 19 9 47% 
Negative Positive 0 0% 0 0 0% 
Negative Negative 422 20% 35 2 6% 
Total   210 100.0% 98  52 53% 
1 includes samples with equivocal Kalon TM result 
2 includes samples with equivocal HerpeSelect ® result 
 
Sensitivity and specificity 
A sub-set of 19 samples with discordant ELISA results, 44 samples with concordant 
positive ELISA results, and 35 samples with concordant negative ELISA results were 
compared with WB (see table 1). Using the data in this table, sensitivity and specificity 
were calculated using a method which accounts for this sampling strategy12 (see table 
2).According to the manufacturer’s instructions, the sensitivity of HerpeSelect® was 98% 
(95% confidence interval [CI]: 95-100) and the specificity was 61% (95%CI: 48-74). The 
sensitivity of the Kalon™ assay was 89% (95%CI: 83-94) and its specificity was 85% 
(95%CI: 61-100).   
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Table 2.  Sensitivity and Specificity of HerpeSelect ® and KalonTM compared with 
Western blot as a gold standard (see example of detailed calculations in Appendix I) 
 Sensitivity % 
(95% CI)  
Specificity %  
(95% CI) 
Correctly 
classified % 
Standard testing    
HerpeSelect ® >1.1 98 
(95-100) 
61 
(48-74) 
80 
KalonTM >1.1 89 
(83-94) 
85 
(61-100) 
80 
Modified cut-off value    
HerpeSelect ® ≥3.5 94 
(89-100) 
87 
(67-100) 
85 
HerpeSelect ® ≥3.3 96 
(92-100.) 
87 
(67-100) 
86 
KalonTM ≥1.0 92 
(87-97) 
75 
(49-100.) 
83 
CI, Confidence Interval 
 
Because both HerpeSelect® and Kalon™ yield continuous results based on OD 
readings, it was possible to explore the sensitivity and specificity of the test depending 
on the cut-off value chosen to define a positive test.  Initially, we examined the higher 
cut-off value for HerpeSelect® of ≥ 3.5, which has been proposed by others13. While this 
resulted in a decreased sensitivity (94%), the specificity was substantially improved 
(87%).  Further exploration using ROC curves showed that 3.3 was the cut-off value for 
optimal sensitivity (96%) and specificity (87%), correctly classifying 86% of samples.  For 
Kalon™, further interpretation of the ROC curve suggested that there was nothing to be 
gained in terms of sensitivity by changing the cut-off above or below the recommended 
index of 1.1.   We subsequently analysed whether using two ELISAs in combination 
improved sensitivity and specificity when compared to WB. The best combination was 
obtained when using HerpeSelect® at increased cut-off (>3.5) followed by testing of “low 
positive” and equivocal samples with Kalon™, yielding sensitivity of 92% (95%CI: 82-98) 
and specificity of 91% (95%CI: 79-98%). Using this approach 22 (10%) of the original 
samples tested by HerpeSelect would have required retesting with Kalon. 
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Effect of age and HIV-1 serostatus on assay performance  
 
In an exploratory analysis, we investigated the effect of age and HIV-1 serostatus on 
assay performance (see table 3). The sensitivity of both tests was lower in the age group 
<25 years compared to those in the age group ≥25 years. Conversely, specificity was 
higher for both tests in the <25 years age group, compared to the older age group. The 
sensitivity of HerpeSelect® in HIV-1 seropositive specimens was high (100%). By 
contrast, its specificity was substantially lower in specimens of participants co-infected 
with HIV-1 (30%), but was improved by raising the cut-off to ≥3.5 (80%). The 
performance of Kalon™ was broadly comparable (sensitivity 91%, specificity 72%).   
 
Table 3. Sensitivity and Specificity of HerpeSelect® and KalonTM by age and HIV-1 
status. 
 Age HIV-1 
 <25 years ≥25 years HIV 
seronegative 
HIV 
seropositive 
Sensitivity %      
HerpeSelect® >1.1 95 100 100 100 
HerpeSelect® >3.5 92 96 98 97 
KalonTM 82 91 80 91 
Specificity %      
HerpeSelect® >1.1 68 55 100 30 
HerpeSelect® >3.5 87 93 100 80 
KalonTM 87 86 100 72 
 
 
Table 4 summarises the distribution of index values for samples that gave false positive 
results by either test when compared with WB.  When comparing these values by age 
group, more false positive samples had index values in the  low range (1.1-2.0) in the 
younger age group compared to the older age group, when tested  by HerpeSelect® (4 
vs. 2).   This was not true for Kalon™.  In the false positive samples for which we had 
HIV-1 positive results, all four false positive samples (3 HerpeSelect®, 1 Kalon™) were 
HIV-1 positive. 
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Table 4.  Index values giving false positive results for each of the tests. 
 No. of samples in each category of index values 
 1.1-2.0 2.01-3.0 >3.0 Total 
HerpeSelect 6 2 4 12 
Kalon 1 2 0 3 
 
 
DISCUSSION 
 
The sensitivity of HerpeSelect® and Kalon™ observed in this study is high and similar to 
previous observations from other African settings where both HSV and HIV-1 prevalence 
are high4, 13, 14, and compares favourably with the results from industrialised countries15.   
 
We found a wide variation in specificity between the two tests, with HerpeSelect® 
demonstrating a high rate of false positive results, using the cut-off value recommended 
by the manufacturer. This resulted in an overestimation of seroprevalence in this 
population by as much as 14%. This is in contrast to observations by Hogrefe et al  who 
found a specificity of 100% in sera from South Africa and Zimbabwe5, although this was 
similar to observations from other studies in Uganda, Kenya, Zambia, Benin and Nigeria, 
where specificity was as low as 40%-70%4, 6, 7, 13.   
 
There are several possible explanations for the higher sensitivity but lower specificity of 
HerpeSelect® compared with Kalon. One explanation is that HerpeSelect® is more 
sensitive than Kalon™, and even WB, in detecting early seroconversion. A study 
comparing the median time to seroconversion of the three assays found that this was 
significantly longer for Kalon™ (120 days) and WB (87 days, p=0.004), than for 
HerpeSelect® (21 days, p<0.001)16. A recent study among African patients with genital 
ulcer disease also found that rates of HSV-2 seroconversion in cases of documented 
first episodes of genital HSV-2 were significantly higher by HerpeSelect® compared to 
Kalon™ (77% vs. 23% at Day 14)17. The high HSV-2 prevalence in this population 
suggests that seroconversion is not a rare event. In addition, 50% of the HerpeSelect® 
false positive tests had readings in the low positive range, which may be suggestive of 
early infection13. However, for this to be true, we would have expected to observe higher 
false positive rate in the younger age group, compared to the older age group.  This was 
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not the case in our study. In fact, we observed a lower sensitivity (of both assays) in the 
younger population compared to the older population. 
 
An alternative explanation for the differences in specificity could be cross reactivity with 
other infections, including HSV-1 or HIV-1.  While the glycoprotein-G2 tests are generally 
quite specific for HSV-2, one study found that, in patients with cultured-documented 
recurrent genital HSV-1 infection, the specificity of Kalon™ was 100%, whilst the 
specificity of HerpeSelect® was slightly lower (93%)16. Golden et al showed the impact 
of HSV-1 on lowering the specificity of HerpeSelect ® in male STD clients18. We were 
unable to test whether there was cross-reactivity with HSV-1 because of the high 
prevalence of HSV-1 (98% of samples tested by WB) in this population. Perhaps a more 
plausible explanation relates to the presence of circulating non-specific antibodies, which 
could either could be the result of hyperglobulinaemia secondary to immune activation 
caused by HIV-1, or even could be the antibodies to HIV-1 themselves, which might 
cross react with the G2-specific portion of the test19, 20.   Specificity was also shown to be 
lower in HIV-1 seropositive samples in the analysis of samples from the Four African City 
Study4, for both tests, but substantially lower for HerpeSelect®.  This is in contrast to 
Laeyendecker et al who did not observe any effect of HIV-1 serostatus on test 
performance, when comparing median index values for HerpeSelect® in HIV-1 infected 
and uninfected individuals14. A further study by the same group among Ugandan 
subjects did not reveal differences in assay performance by HIV-1 serostatus7.  
However, HIV-1 prevalence was lower in this Ugandan population (33%) than in our 
South African population (52%).  Higher rates of co-infection with HIV-1 in the older age 
groups may also explain the higher specificity observed in the younger age group in our 
study.  While not conclusive, we also noted in our study that all HSV-2 false positive 
tests with available HIV-1 results were indeed HIV-1 positive. 
 
A third possible explanation is geographical variation in HSV-2 strains.  Although data 
from Europe suggest that the gG2 epitope is fairly well conserved21, strains from African 
populations have not been sequenced.  These strains may be more diverse and have 
different affinities for both the ELISA assays, as well as the WB. Certainly, atypical WB 
profiles were observed in this study (data not shown), and have been reported by other 
investigators 5, 13,6  
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Raising the cut-off value for defining positive results for HerpeSelect® appeared to 
improve the specificity without compromising sensitivity too much and compares well 
with the Kalon™ assay. This approach was eventually used as the strategy for 
identifying participants with HSV-2 for inclusion in two large multi-centre HSV-2 
suppressive treatment trials22, 23. We showed that the same approach did not yield 
similar improvements in performance for the Kalon™ assay.  This may be because this 
test is already fairly specific for HSV-2 and further improvements in specificity result in 
losses in sensitivity. 
 
Finally we showed that using a combination of two tests resulted in high levels of 
sensitivity and specificity being obtained when compared with WB.  Using HerpeSelect® 
with a higher cut-off and testing all equivocal results with Kalon™ as the resolver test 
resulted in a testing algorithm which was suitably sensitive and specific, and only 
required re-testing of 10% of the original sample. Economic and operational research will 
be warranted to determine the role of these strategies in other settings. The demand for 
improved HSV-2 testing strategies is likely to grow with increasing awareness of the high 
prevalence of HSV-2 in the developing world, and its association with HIV-1 
transmission. 
 
In conclusion, high rates of false positivity continue to challenge the performance of the 
HerpeSelect® assay in African sera.  In particular, the poor specificity of the test in HIV-1 
seropositive populations warrants its cautionary use and a larger scale investigation.  
However, adjusting the cut-off and/or using a two-test testing algorithm resulted in 
significant improvements when compared with using either test alone.  The feasibility 
and cost-benefit of such approaches should be further evaluated. 
 
Word count = 2,568 
 
Key messages 
• HSV-2 seroprevalence ranged from 66% with the KalonTM ELISA to 80% with the 
HerpeSelect ® ELISA. 
• HerpeSelect® had a high sensitivity but lower specificity while KalonTM was less 
sensitive but more specific. 
• HIV-1 infection appeared to reduce the specificity of HerpeSelect®.  
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• Specificity was improved by raising the cut-off index for determination of a positive 
result for HerpeSelect® (to ≥3.5), but not for KalonTM. 
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Appendix I: Example of calculation of sensitivity & specificity for HerpeSelect® 
based on Hawkins et al. 
Index test Resolver test (WB)   
(Focus) Positive  Negative Total 
  Kalon   
 Positive Negative Total Positive Negative Total  
Positive 0.612 0.0681 0.680 0.045 0.075 0.120 0.800
Negative 0.000 0.011 0.011 0.000 0.189 0.189 0.200
Total 0.612 0.079 0.691 0.045 0.264 0.309 1.000
 
 
These steps were followed to calculate sensitivity and specificity for Focus ®: 
Step 1. Using data from table 1 fill each of the cells. For example1, the value for this cell 
is calculated as 0.143 (proportion of samples with this result i.e. 30/210 HerpeSelect ® 
positive, Kalon TM negative) X 0.474 (proportion of these samples correctly resolved on 
WB. i.e. 9/19) = 0.680 
Step 2. HerpeSelect ® sensitivity is total positive out of total i.e. 0.680/0.691 = 98.3%. 
Similarly, specificity is total negative out of total samples i.e.0.189/0.309=61.1% 
 
 
